Literature DB >> 23904418

Successful treatment of disseminated mucormycosis in a neutropenic patient with T-cell acute lymphoblastic leukaemia.

Chelsea Guymer1, Sanjeev Khurana, Ram Suppiah, Iain Hennessey, Celia Cooper.   

Abstract

Mucormycosis is a rare angioinvasive fungal infection, more commonly seen in immunosuppressed patients, with reported mortality rates of 95% in disseminated disease. We present a case report of a patient with T-cell acute lymphoblastic leukaemia who developed disseminated infection with mucormycosis (involving the pancreas, left occipital lobe, right lower lobe of lung, appendix and right kidney) after having completed induction and consolidation chemotherapy. Growth of Lichtheimia corymbifera was initially isolated following a right pleural tap with fungal elements identified repeatedly on subsequent pathology specimens. Following radical surgical debridement and concurrent treatment with combination antifungal therapy, the patient survived. This case demonstrates that aggressive multisite surgical de-bulking of disseminated fungal foci, in conjunction with combination antifungal therapy and reversal of immunosuppression, can result in survival despite the grave prognosis associated with disseminated mucormycosis.

Entities:  

Mesh:

Year:  2013        PMID: 23904418      PMCID: PMC3736398          DOI: 10.1136/bcr-2013-009577

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  A rare presentation of zygomycosis (mucormycosis) and review of the literature.

Authors:  M Karanth; P Taniere; J Barraclough; J A Murray
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

2.  Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis).

Authors:  Thomas J Walsh; Maria N Gamaletsou; Michael R McGinnis; Randall T Hayden; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

3.  Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis.

Authors:  Thomas J Walsh; Bruce E Bloom; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

4.  Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia.

Authors:  V Rickerts; J Atta; S Herrmann; V Jacobi; E Lambrecht; R Bialek; G Just-Nübling
Journal:  Mycoses       Date:  2006       Impact factor: 4.377

Review 5.  Pulmonary mucormycosis: results of medical and surgical therapy.

Authors:  M Tedder; J A Spratt; M P Anstadt; S S Hegde; S D Tedder; J E Lowe
Journal:  Ann Thorac Surg       Date:  1994-04       Impact factor: 4.330

Review 6.  Mucormycosis in hematologic patients.

Authors:  Livio Pagano; Massimo Offidani; Luana Fianchi; Annamaria Nosari; Anna Candoni; Marco Picardi; Laura Corvatta; Domenico D'Antonio; Corrado Girmenia; Pietro Martino; Albano Del Favero
Journal:  Haematologica       Date:  2004-02       Impact factor: 9.941

Review 7.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

8.  Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

Authors:  Andrea V Page; W Conrad Liles
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

9.  Mucormycosis-associated fungal infections in patients with haematologic malignancies.

Authors:  I O Kara; Y Tasova; A Uguz; B Sahin
Journal:  Int J Clin Pract       Date:  2007-03-16       Impact factor: 2.503

Review 10.  Zygomycosis in children: a systematic review and analysis of reported cases.

Authors:  Theoklis E Zaoutis; Emmanuel Roilides; Christine C Chiou; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Priya A Prasad; Jaclyn H Chu; Thomas J Walsh
Journal:  Pediatr Infect Dis J       Date:  2007-08       Impact factor: 2.129

View more
  6 in total

1.  Novel therapeutic use of Versajet for intestinal mucormycosis.

Authors:  William Calvert; Dhanya Mullassery; Rajeev Shukla; Graham Lamont
Journal:  BMJ Case Rep       Date:  2014-03-03

2.  Bacteriome and mycobiome associations in oral tongue cancer.

Authors:  Pranab K Mukherjee; Hannah Wang; Mauricio Retuerto; Huan Zhang; Brian Burkey; Mahmoud A Ghannoum; Charis Eng
Journal:  Oncotarget       Date:  2017-10-19

3.  Disseminated Mucormycosis in Immunocompromised Children: Are New Antifungal Agents Making a Difference? A Multicenter Retrospective Study.

Authors:  Sarah Elitzur; Salvador Fischer; Nira Arad-Cohen; Assaf Barg; Miriam Ben-Harosh; Dana Danino; Ronit Elhasid; Aharon Gefen; Gil Gilad; Itzhak Levy; Yael Shachor-Meyouhas; Sigal Weinreb; Shai Izraeli; Shlomit Barzilai-Birenboim
Journal:  J Fungi (Basel)       Date:  2021-02-25

4.  Case report: A rare case of pulmonary mucormycosis caused by Lichtheimia ramosa in pediatric acute lymphoblastic leukemia and review of Lichtheimia infections in leukemia.

Authors:  Guo-Qian He; Ling Xiao; Zhen Pan; Jian-Rong Wu; Dong-Ni Liang; Xia Guo; Ming-Yan Jiang; Ju Gao
Journal:  Front Oncol       Date:  2022-08-15       Impact factor: 5.738

5.  Clinical presentations, diagnosis, management, and outcomes of renal mucormycosis: An overview of case reports.

Authors:  Mojtaba Didehdar; Zahra Chegini; Amin Khoshbayan; Alireza Moradabadi; Aref Shariati
Journal:  Front Med (Lausanne)       Date:  2022-08-24

6.  Renal mucormycosis in immunocompromised patient, treated with Robotic Nephrectomy: Case report and review of articles.

Authors:  Sameer Munshi; Maher Moazin; Saleh Abu-Daff; Muhammad Amin Urrahman; Othman Jamal Alamoudi; Abdulaziz Hamad Almehrej
Journal:  Urol Case Rep       Date:  2017-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.